Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-03-08 22:45 |
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 202…
|
English | 566.8 KB | ||
| 2023-03-06 22:30 |
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Cor…
|
French | 257.2 KB | ||
| 2023-03-06 22:30 |
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Cor…
|
English | 257.2 KB | ||
| 2023-03-01 22:30 |
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March…
|
English | 71.4 KB | ||
| 2023-03-01 22:30 |
Cellectis présentera ses résultats financiers du quatrième trimestre et de l’an…
|
French | 66.4 KB | ||
| 2023-02-09 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 83.7 KB | ||
| 2023-02-09 22:30 |
Monthly information on share capital and company voting rights
|
English | 76.2 KB | ||
| 2023-02-08 01:01 |
Cellectis annonce le règlement livraison de son offre d’ADS et l’exercice de l’…
|
French | 438.3 KB | ||
| 2023-02-08 01:01 |
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Op…
|
English | 83.5 KB | ||
| 2023-02-03 15:34 |
Cellectis complète l’annonce des modalités définitives de son offre d’ADS avec …
|
French | 195.9 KB | ||
| 2023-02-03 15:33 |
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering wit…
|
English | 131.2 KB | ||
| 2023-02-03 06:49 |
Cellectis annonce les modalités définitives de son offre d’ADS
|
French | 107.0 KB | ||
| 2023-02-03 06:48 |
Cellectis Announces Pricing of Follow-On Offering
|
English | 89.7 KB | ||
| 2023-02-02 22:01 |
Cellectis annonce le lancement d’une nouvelle offre d’ADS
|
French | 100.4 KB | ||
| 2023-02-02 22:01 |
Cellectis Announces Launch of Follow-On Offering
|
English | 89.1 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
